Clinical significance of hypertension in patients with different types of cancer treated with antiangiogenic drugs (Review)
- Authors:
- Mei Dong
- Rujian Wang
- Ping Sun
- Dongxia Zhang
- Zhenzhen Zhang
- Jing Zhang
- Gary Tse
- Lin Zhong
-
Affiliations: Department of Cardiology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China, Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China, Tianjin Key Laboratory of Ionic‑Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, P.R. China - Published online on: February 23, 2021 https://doi.org/10.3892/ol.2021.12576
- Article Number: 315
-
Copyright: © Dong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Vasudev NS and Reynolds AR: Anti-angiogenic therapy for cancer: Current progress, unresolved questions and future directions. Angiogenesis. 17:471–494. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Brinda BJ, Viganego F, Vo T, Dolan D and Fradley MG: Anti-VEGF-induced hypertension: A review of pathophysiology and treatment options. Curr Treat Options Cardiovasc Med. 18:332016. View Article : Google Scholar : PubMed/NCBI | |
|
Eskens FA and Verweij J: The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review. Eur J Cancer. 42:3127–3139. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Abi Aad S, Pierce M, Barmaimon G, Farhat FS, Benjo A and Mouhayar E: Hypertension induced by chemotherapeutic and immunosuppresive agents: A new challenge. Crit Rev Oncol Hematol. 93:28–35. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Neagoe PE, Lemieux C and Sirois MG: Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and −2 heterodimer. J Biol Chem. 280:9904–9912. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Neves KB, Rios FJ, Jones R, Evans TRJ, Montezano AC and Touyz RM: Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury. Cardiovasc Res. 115:978–988. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hasinoff BB and Patel D: Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib. Cardiovasc Toxicol. 10:1–8. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Semeniuk-Wojtaś A, Lubas A, Stec R, Szczylik C and Niemczyk S: Influence of tyrosine kinase inhibitors on hypertension and nephrotoxicity in metastatic renal cell cancer patients. Int J Mol Sci. 17:20732016. View Article : Google Scholar | |
|
U.S. Department of Health and Human Services, . Common Terminology Criteria For Adverse Events (CTCAE). Version 5.0, 2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5×7.pdfNovember 27–2017 | |
|
Bæk Møller N, Budolfsen C, Grimm D, Krüger M, Infanger M, Wehland M and Magnusson N: Drug-induced hypertension caused by multikinase inhibitors (sorafenib, sunitinib, lenvatinib and axitinib) in renal cell carcinoma treatment. Int J Mol Sci. 20:47122019. View Article : Google Scholar | |
|
Tadic M, Cuspidi C, Belyavskiy E and Grassi G: Intriguing relationship between antihypertensive therapy and cancer. Pharmacol Res. 141:501–511. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Pinter M, Kwanten WJ and Jain RK: Renin-angiotensin system inhibitors to mitigate cancer treatment-related adverse events. Clin Cancer Res. 24:3803–3812. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Nakaya A, Kurata T, Yokoi T, Iwamoto S, Torii Y, Katashiba Y, Ogata M, Hamada M, Kon M and Nomura S: Retrospective analysis of bevacizumab-induced hypertension and clinical outcome in patients with colorectal cancer and lung cancer. Cancer Med. 5:1381–1387. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X, Qin S, Wang Z, Xu J, Xiong J, Bai Y, Wang Z, Yang Y, Sun G, Wang L, et al: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: A cohort study. J Hematol Oncol. 10:1532017. View Article : Google Scholar : PubMed/NCBI | |
|
Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, et al: Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 375:2246–2254. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, et al: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet. 370:2103–2111. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Rini BI, Melichar B, Ueda T, Grünwald V, Fishman MN, Arranz JA, Bair AH, Pithavala YK, Andrews GI, Pavlov D, et al: Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: A randomised double-blind phase 2 trial. Lancet Oncol. 14:1233–1242. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, et al: Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol. 28:1061–1068. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Akaza H, Naito S, Ueno N, Aoki K, Houzawa H, Pitman Lowenthal S and Lee SY: Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: Efficacy, safety and biomarker analyses in 1689 consecutive patients. Jpn J Clin Oncol. 45:576–583. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J and Small EJ: Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206. J Clin Oncol. 28:2137–2143. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ravaud A and Sire M: Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer. Ann Oncol. 20:966–967. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Donskov F, Michaelson MD, Puzanov I, Davis MP, Bjarnason GA, Motzer RJ, Goldstein D, Lin X, Cohen DP, Wiltshire R and Rini BI: Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. Br J Cancer. 113:1571–1580. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Goldstein D, Rosenberg JE, Figlin RA, Townsend RR, McCann L, Carpenter C and Pandite L: Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma? Eur J Cancer. 53:96–104. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, Sun G, Yang Y, Wang L, Xu N, et al: Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: Results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 31:3219–3225. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR, et al: Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 383:31–39. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol. 15:1224–1235. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, et al: Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 34:1448–1454. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, et al: BEYOND: A randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol. 33:2197–2204. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R and Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N and Manegold C: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 27:1227–1234. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Lu S, Chang J, Liu X, Shi J, Lu Y, Li W, Yang JJ, Zhou J, Wang J, An T, et al: Randomized, double-blind, placebo-controlled, multicenter phase II study of fruquintinib after two prior chemotherapy regimens in chinese patients with advanced nonsquamous nonsmall-cell lung cancer. J Clin Oncol. 36:1207–1217. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, et al: Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): Interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 20:625–635. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou M, Chen X, Zhang H, Xia L, Tong X, Zou L, Hao R, Pan J, Zhao X, Chen D, et al: China national medical products administration approval summary: Anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy. Cancer Commun (Lond). 39:362019. View Article : Google Scholar : PubMed/NCBI | |
|
Goodwin R, Ding K, Seymour L, LeMaitre A, Arnold A, Shepherd FA, Dediu M, Ciuleanu T, Fenton D, Zukin M, et al: Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC clinical trials group study BR24. Ann Oncol. 21:2220–2226. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Koyama N: Adverse cardiovascular events predict survival benefit in non-small lung cancer patients treated with bevacizumab. Cancer Biomark. 14:259–265. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lin H, Li L, Luo S, Zhou S, Shen R, Yang H, Chen H and Xie X: Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer. Oncology. 8:1141–1155. 2017. | |
|
Sun L, Ma JT, Zhang SL, Zou HW and Han CB: Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: A systematic review and meta-analysis. Med Oncol. 32:4732015. View Article : Google Scholar : PubMed/NCBI | |
|
Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, Burcoveanu D, Fukuoka M, Besse B and Pignon JP; meta-analysis of bevacizumab in advanced NSCLC collaborative group, : Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol. 24:20–30. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Brahmer JR, Dahlberg SE, Gray RJ, Schiller JH, Perry MC, Sandler A and Johnson DH: Sex differences in outcome with bevacizumab therapy: Analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern cooperative oncology group trial 4599. J Thorac Oncol. 6:103–108. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Leighl NB, Zatloukal P, Mezger J, Ramlau R, Moore N, Reck M and Manegold C: Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL). J Thorac Oncol. 5:1970–1976. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Price TJ, Zannino D, Wilson K, Simes RJ, Cassidy J, Van Hazel GA, Robinson BA, Broad A, Ganju V, Ackland SP and Tebbutt NC: Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: A subgroup analysis from the AGITG MAX trial: An international randomised controlled trial of capecitabine, bevacizumab and mitomycin C. Ann Oncol. 23:1531–1536. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Aparicio T, Bouché O, Taieb J, Maillard E, Kirscher S, Etienne PL, Faroux R, Khemissa Akouz F, El Hajbi F, Locher C, et al: Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: A randomized phase II trial-PRODIGE 20 study results. Ann Oncol. 29:133–138. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Colangelo LH, Lopa SH, Petrelli NJ, Goldberg RM, Atkins JN, Seay TE, et al: Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol. 27:3385–3390. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, et al: Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 16:499–508. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Grothey A, Cutsem EV, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et al: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 381:303–312. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Xu RH, Li J, Bai Y, Xu J, Liu T, Shen L, Wang L, Pan H, Cao J, Zhang D, et al: Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: A phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. 10:222017. View Article : Google Scholar : PubMed/NCBI | |
|
Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C and Cascinu S: Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol. 20:227–230. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Tahover E, Uziely B, Salah A, Temper M, Peretz T and Hubert A: Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients. Med Oncol. 30:3272013. View Article : Google Scholar : PubMed/NCBI | |
|
da Silva WC, de Araujo VE, Lima EMEA, Dos Santos JBR, Silva MRRD, Almeida PHRF, de Assis Acurcio F, Godman B, Kurdi A, Cherchiglia ML and Andrade EIG: Comparative effectiveness and safety of monoclonal antibodies (bevacizumab, cetuximab, and panitumumab) in combination with chemotherapy for metastatic colorectal cancer: A systematic review and meta-analysis. BioDrugs. 32:585–606. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hurwitz HI, Tebbutt NC, Kabbinavar F, Giantonio BJ, Guan ZZ, Mitchell L, Waterkamp D and Tabernero J: Efficacy and safety of bevacizumab in metastatic colorectal cancer: Pooled analysis from seven randomized controlled trials. Oncologist. 18:1004–1012. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Galfrascoli E, Piva S, Cinquini M, Rossi A, La Verde N, Bramati A, Moretti A, Manazza A, Damia G, Torri V, et al: Risk/benefit profile of bevacizumab in metastatic colon cancer: A systematic review and meta-analysis. Dig Liver Dis. 43:286–294. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Tahover E, Hubert A, Temper M, Salah A, Peretz T, Hamburger T and Uziely B: An observational cohort study of bevacizumab and chemotherapy in metastatic colorectal cancer patients: Safety and efficacy with analysis by age group. Target Oncol. 10:55–63. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Tabernero J, Hozak RR, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Prausová J, et al: Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study. Ann Oncol. 602–609. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Obermannová R, Van Cutsem E, Yoshino T, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, Garcia Alfonso P, Portnoy D, Cohn A, et al: Subgroup analysis in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. Ann Oncol. 27:2082–2090. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D, et al: Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): An open-label, randomised phase 3 trial. Lancet Oncol. 14:1077–1085. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Shah SR, Gressett Ussery SM, Dowell JE, Marley E, Liticker J, Arriaga Y and Verma U: Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension. Ann Oncol. 24:960–965. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, et al: Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 16:619–629. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, et al: Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol. 14:29–37. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Al-Batran SE, Lange T, Dietrich G, Stoehlmacher J, et al: Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): A randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 16:1355–1369. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Morse MA, Sun W, Kim R, He AR, Abada PB, Mynderse M and Finn RS: The role of angiogenesis in hepatocellular carcinoma. Clin Cancer Res. 25:912–920. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, et al: Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 379:54–63. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, et al: Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 389:56–66. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, et al: Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 16:859–870. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, et al: Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20:282–296. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Akutsu N, Sasaki S, Takagi H, Motoya M, Shitani M, Igarashi M, Hirayama D, Wakasugi H, Yamamoto H, Kaneto H, et al: Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy. Int J Clin Oncol. 20:105–110. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Meyer T, Fox R, Ma YT, Ross PJ, James MW, Sturgess R, Stubbs C, Stocken DD, Wall L, Watkinson A, et al: Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): A randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2:565–575. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Aalders KC, Tryfonidis K, Senkus E and Cardoso F: Anti- angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives. Cancer Treat Rev. 53:98–110. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, et al: Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 366:310–320. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, et al: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 28:3239–3247. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, et al: RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 29:1252–1260. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Fan M, Zhang J, Wang Z, Wang B, Zhang Q, Zheng C, Li T, Ni C, Wu Z, Shao Z and Hu X: Phosphorylated VEGFR2 and hypertension: Potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy. Breast Cancer Res Treat. 143:141–151. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, et al: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 26:4672–4678. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Cortes J, Calvo V, Ramírez-Merino N, O'Shaughnessy J, Brufsky A, Robert N, Vidal M, Muñoz E, Perez J, Dawood S, et al: Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: A meta-analysis. Ann Oncol. 23:1130–1137. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Pivot X, Schneeweiss A, Verma S, Thomssen C, Passos-Coelho JL, Benedetti G, Ciruelos E, von Moos R, Chang HT, Duenne AA and Miles DW: Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO. Eur J Cancer. 47:2387–2395. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, et al: Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicentre, open-label, phase 3, randomised controlled trial. Lancet. 393:2404–2415. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yang L, Chen Y, Qin S, Wang L, Hua H, Liu X, et al: Clinical observation on hypertenison induced by anti-angiogenic agents for cancer. Chin Clin Oncol. 19:603–607. 2014. | |
|
Yang WY, Melgarejo JD, Thijs L, Zhang ZY, Boggia J, Wei FF, Hansen TW, Asayama K, Ohkubo T, Jeppesen J, et al: Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes. JAMA. 322:409–420. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Choueiri TK, Vaziri SAJ, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, et al: von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol. 180:860–866. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Li S, Zhu Y, Liang X, Meng H, Chen J, Zhang D, Guo H and Shi B: Incidence and risk of sorafenib-induced hypertension: A systematic review and meta-analysis. J Clin Hypertens (Greenwich). 16:177–185. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Frey MK, Dao F, Olvera N, Konner JA, Dickler MN and Levine DA: Genetic predisposition to bevacizumab-induced hypertension. Gynecol Oncol. 147:621–625. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Scagliotti GV, Krzakowski M, Szczesna A, Strausz J, Makhson A, Reck M, Wierzbicki RF, Albert I, Thomas M, Miziara JE, et al: Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: A phase III trial. J Clin Oncol. 30:2070–2078. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Shen L, Li J, Xu J, Pan H, Dai G, Qin S, Wang L, Wang J, Yang Z, Shu Y, et al: Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: Randomized, double-blind, phase III study (AVATAR study). Gastric Cancer. 18:168–176. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Schwartzberg LS, Tauer KW, Hermann RC, Makari-Judson G, Isaacs C, Beck JT, Kaklamani V, Stepanski EJ, Rugo HS, Wang W, et al: Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. Clin Cancer Res. 19:2745–2754. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Crown JP, Diéras V, Staroslawska E, Yardley DA, Bachelot T, Davidson N, Wildiers H, Fasching PA, Capitain O, Ramos M, et al: Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol. 31:2870–2878. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Syrigos KN, Karapanagiotou E, Boura P, Manegold C and Harrington K: Bevacizumab-induced hypertension: Pathogenesis and management. BioDrugs. 25:159–169. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, et al: 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 39:3021–3104. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, Ivy SP, Leier CV, Lindenfeld J, Liu G, et al: Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 102:596–604. 2010. View Article : Google Scholar : PubMed/NCBI |
